Abcam, ab309150, Anti-Complement factor B antibody [EPR27443-6] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CFAB antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27443-6,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat, Human, Mouse,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Complement factor B also known as CFB protein is a component of the complement system. It plays an important role in the alternative pathway. This protein with a molecular mass of approximately 93 kDa is produced mainly in the liver and expresses in various tissues throughout the body. Factor B comprises several domains including the von Willebrand factor type A domain essential for its activity. CFB engages in protein-protein interactions important for the function of the complement cascade.
Biological function summary
Complement factor B is essential in the immune system. It participates in the formation of the C3 convertase complex which is an important step in the amplification of the complement cascade. This protein contributes to the opsonization and clearance of pathogens assisting in the immune response. CFB binds with complement component C3b to participate in the alternative pathway which does not require antibody presence for activation.
Pathways
Complement factor B is part of the innate immune pathway. It helps mediate the alternative complement pathway acting as an amplifier of immune responses. This pathway interacts closely with the classical and lectin pathways ensuring a versatile defense mechanism. Factor D for example also plays a complementary role by cleaving factor B when bound to C3b to form C3 convertase a critical step in propagating the immune response.
Complement factor B associates with kidney-related diseases like atypical hemolytic uremic syndrome (aHUS). Mutations in CFB can lead to deregulated complement activation contributing to pathological conditions like age-related macular degeneration (AMD). The relationship with protein C3 is important in these disorders as both factor B and C3 engage in interactions that when dysfunctional influence disease outcomes. Understanding these interactions can help develop targeted therapies such as anti-complement agents to modulate the complement system in these diseases.